Understanding the Genetics of Age-Related Macular Degeneration: Gregory S. Hageman, PhD

Video

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed the research his team has been conducting in AMD.

“We have teams that are pushing towards both [factor H on chromosome 1 and ARMS2 and HTRA1 on chromosome 10]. And I would say we have a very robust understanding of what the disease process is what's happening in the back of the eye, we have a lot of clinical correlates, we understand that these are very much different biological diseases [that cause AMD] and the sad part is a lot of patients will have some mix of both. So down the line, we'll have to think about therapies.”

Loci in chromosome 10 and chromosome 1 have previously been identified as important in the role of developing age-related macular degeneration (AMD). Recent research into the HTRA1 and ARMS2 genes in the chromosome 10 locus have elucidated the role of these genes in developing AMD.

To learn more about the implications of these findings, GeneTherapyLive spoke with Brandi. L Williams, PhD, research director, and Gregory S. Hageman, PhD, executive director, Steele Center for Translational Medicine, both from the John A. Moran Eye Center. 

Williams and Hageman discussed the paper they recently published in PNAS which was the culmination of 15 years of research, providing some background on the Moran Center and previous research in AMD.

REFERENCE
Williams BL, Seager NA, Gardiner JD, et al. Chromosome 10q26–driven age-related macular degeneration is associated with reduced levels of HTRA1 in human retinal pigment epithelium. PNAS. 2021;118(30) e2103617118. doi:10.1073/pnas.2103617118
Recent Videos
Carol Miao, PhD, a principal investigator at Seattle Children’s Research Institute
Lucas Harrington, PhD, the cofounder and chief scientific officer of Mammoth Biosciences
Miloš Miljković, MD, on mRNA-CAR-T Descartes-08's Potential for Treating Myasthenia Gravis
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
© 2024 MJH Life Sciences

All rights reserved.